Both MC5r and A2Ar are required for protective regulatory immunity in the spleen of post-experimental autoimmune uveitis in mice

Journal of Immunology

Volumn 191, Issue 8, 2013, Pages 4103-4111

  Lee, Darren J ^a   Taylor, Andrew W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE 2A RECEPTOR; ADENOSINE RECEPTOR; ALPHA INTERMEDIN; AUTOANTIGEN; CD11B ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MELANOCORTIN 5 RECEPTOR; PEPTIDES AND PROTEINS; PROTEIN F4 80; PROTEIN LY 6C; PROTEIN LY 6G; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE UVEITIS; CONTROLLED STUDY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE ACTIVATION; UVEORETINITIS;

5'-NUCLEOTIDASE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, CD4; ANTIGENS, LY; APYRASE; AUTOANTIGENS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; EYE; EYE PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; INFLAMMATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, ADENOSINE A2A; RECEPTORS, MELANOCORTIN; RETINOL-BINDING PROTEINS; SELF TOLERANCE; SPLEEN; T-LYMPHOCYTES, REGULATORY; UVEITIS;

EID: 84885452753     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300182     Document Type: Article

References (50)

1. Caspi, R. R., F. G. Roberge, C. C. Chan, B. Wiggert, G. J. Chader, L. A. Rozenszajn, Z. Lando, and R. B. Nussenblatt. 1988. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 140: 1490-1495.
2. Kitaichi, N., K. Namba, and A. W. Taylor. 2005. Inducible immune regulation following autoimmune disease in the immune-privileged eye. J. Leukoc. Biol. 77: 496-502.
3. Taylor, A. W. 2007. Ocular immunosuppressive microenvironment. Chem. Immunol. Allergy 92: 71-85.
4. Lee, D. J., D. J. Biros, and A. W. Taylor. 2009. Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis. Int. Immunopharmacol. 9: 1079-1086.
5. Taylor, A. W., D. G. Yee, T. Nishida, and K. Namba. 2000. Neuropeptide regulation of immunity. The immunosuppressive activity of alpha- melanocytestimulating hormone (alpha-MSH). Ann. N. Y. Acad. Sci. 917: 239-247.
6. Taylor, A. W., and N. Kitaichi. 2008. The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy. Brain Behav. Immun. 22: 639-646.
7. Hamrah, P., Z. Haskova, A.W. Taylor, Q. Zhang, B. R. Ksander, and M. R. Dana. 2009. Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection. Transplantation 88: 180-187.
8. Cooray, S. N., and A. J. Clark. 2011. Melanocortin receptors and their accessory proteins. Mol. Cell. Endocrinol. 331: 215-221.
9. Yang, Y. 2011. Structure, function and regulation of the melanocortin receptors. Eur. J. Pharmacol. 660: 125-130.
10. Lee, D. J., and A. W. Taylor. 2011. Following EAU recovery there is an associated MC5r-dependent APC induction of regulatory immunity in the spleen. Invest. Ophthalmol. Vis. Sci. 52: 8862-8867.
11. Peranzoni, E., S. Zilio, I. Marigo, L. Dolcetti, P. Zanovello, S. Mandruzzato, and V. Bronte. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22: 238-244.
12. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166.
13. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
14. Movahedi, K., D. Laoui, C. Gysemans, M. Baeten, G. Stangé, J. Van den Bossche, M. Mack, D. Pipeleers, P. In't Veld, P. De Baetselier, and J. A. Van Ginderachter. 2010. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70: 5728-5739.
15. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802.
16. Zhu, B., J. K. Kennedy, Y. Wang, C. Sandoval-Garcia, L. Cao, S. Xiao, C. Wu, W. Elyaman, and S. J. Khoury. 2011. Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J. Immunol. 187: 2418-2432.
17. Luger, T. A., D. Kalden, T. E. Scholzen, and T. Brzoska. 1999. alphamelanocyte-stimulating hormone as a mediator of tolerance induction. Pathobiology 67: 318-321.
18. Lau, C. H., and A. W. Taylor. 2009. The immune privileged retina mediates an alternative activation of J774A.1 cells. Ocul. Immunol. Inflamm. 17: 380-389.
19. Kawanaka, N., and A.W. Taylor. 2011. Localized retinal neuropeptide regulation of macrophage and microglial cell functionality. J. Neuroimmunol. 232: 17-25.
20. Namba, K., N. Kitaichi, T. Nishida, and A. W. Taylor. 2002. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocytestimulating hormone and transforming growth factor-beta2. J. Leukoc. Biol. 72: 946-952.
21. Streilein, J. W., M. Takeuchi, and A. W. Taylor. 1997. Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity. Hum. Immunol. 52: 138-143.
22. Yin, P., T. M. Luby, H. Chen, B. Etemad-Moghadam, D. Lee, N. Aziz, U. Ramstedt, and M. L. Hedley. 2003. Generation of expression constructs that secrete bioactive alphaMSH and their use in the treatment of experimental autoimmune encephalomyelitis. Gene Ther. 10: 348-355.
23. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
24. Ernst, P. B., J. C. Garrison, and L. F. Thompson. 2010. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J. Immunol. 185: 1993-1998.
25. Sitkovsky, M. V., and A. Ohta. 2005. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol. 26: 299-304.
26. Buscà, R., E. Berra, C. Gaggioli, M. Khaled, K. Bille, B. Marchetti, R. Thyss, G. Fitsialos, L. Larribère, C. Bertolotto, et al. 2005. Hypoxia-inducible factor 1alpha is a new target of microphthalmia- Associated transcription factor (MITF) in melanoma cells. J. Cell Biol. 170: 49-59.
27. Blackburn, M. R., C. O. Vance, E. Morschl, and C. N. Wilson. 2009. Adenosine receptors and inflammation. Handbook Exp. Pharmacol. 215-269.
28. Zanin, R. F., E. Braganhol, L. S. Bergamin, L. F. Campesato, A. Z. Filho, J. C. Moreira, F. B. Morrone, J. Sévigny, M. R. Schetinger, A. T. de Souza Wyse, and A. M. Battastini. 2012. Differential macrophage activation alters the expression profile of NTPDase and ecto-59-nucleotidase. PLoS ONE 7: e31205.
29. Ignar, D. M., J. L. Andrews, M. Jansen, M. M. Eilert, H. M. Pink, P. Lin, R. G. Sherrill, J. R. Szewczyk, and J. G. Conway. 2003. Regulation of TNFalpha secretion by a specific melanocortin-1 receptor peptide agonist. Peptides 24: 709-716.
30. Lam, C. W., M. Perretti, and S. J. Getting. 2006. Melanocortin receptor signaling in RAW264.7 macrophage cell line. Peptides 27: 404-412.
31. Li, D., and A. W. Taylor. 2008. Diminishment of alpha-MSH anti-inflammatory activity in MC1r siRNA-transfected RAW264.7 macrophages. J. Leukoc. Biol. 84: 191-198.
32. Manna, S. K., and B. B. Aggarwal. 1998. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J. Immunol. 161: 2873-2880.
33. Taylor, A. W. 2005. The immunomodulating neuropeptide alpha-melanocytestimulating hormone (alpha-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J. Neuroimmunol. 162: 43-50.
34. Kerr, E. C., B. J. Raveney, D. A. Copland, A. D. Dick, and L. B. Nicholson. 2008. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J. Autoimmun. 31: 354-361.
35. Niederkorn, J. Y. 2007. The induction of anterior chamber-Associated immune deviation. Chem. Immunol. Allergy 92: 27-35.
36. Biros, D. J., K. Namba, and A. W. Taylor. 2006. Alpha-MSH regulates protein ubiquitination in T cells. Cell. Mol. Biol. (Noisy-le-grand) 52: 33-38.
37. Taylor, A., and K. Namba. 2001. In vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). Immunol. Cell Biol. 79: 358-367.
38. Buggy, J. J. 1998. Binding of alpha-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak/STAT pathway. Biochem. J. 331: 211-216.
39. Condamine, T., and D. I. Gabrilovich. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32: 19-25.
40. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
41. Scott, G., L. Cassidy, and Z. Abdel-Malek. 1997. Alpha-melanocyte- stimulating hormone and endothelin-1 have opposing effects on melanocyte adhesion, migration, and pp125FAK phosphorylation. Exp. Cell Res. 237: 19-28.
42. Catania, A., N. Rajora, F. Capsoni, F. Minonzio, R. A. Star, and J. M. Lipton. 1996. The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides 17: 675-679.
43. Kinsey, G. R., L. Huang, K. Jaworska, K. Khutsishvili, D. A. Becker, H. Ye, P. I. Lobo, and M. D. Okusa. 2012. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J. Am. Soc. Nephrol. 23: 1528-1537.
44. Naganuma, M., E. B. Wiznerowicz, C. M. Lappas, J. Linden, M. T. Worthington, and P. B. Ernst. 2006. Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J. Immunol. 177: 2765-2769.
45. Odashima, M., G. Bamias, J. Rivera-Nieves, J. Linden, C. C. Nast, C. A. Moskaluk, M. Marini, K. Sugawara, K. Kozaiwa, M. Otaka, et al. 2005. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 129: 26-33.
46. Dai, S. S., and Y. G. Zhou. 2011. Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury. Rev. Neurosci. 22: 231-239.
47. Day, Y. J., Y. Li, J. M. Rieger, S. I. Ramos, M. D. Okusa, and J. Linden. 2005. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J. Immunol. 174: 5040-5046.
48. Rivo, J., E. Zeira, E. Galun, S. Einav, J. Linden, and I. Matot. 2007. Attenuation of reperfusion lung injury and apoptosis by A2A adenosine receptor activation is associated with modulation of Bcl-2 and Bax expression and activation of extracellular signal-regulated kinases. Shock 27: 266-273.
49. Ohtsuka, T., P. S. Changelian, D. Bouïs, K. Noon, H. Harada, V. N. Lama, and D. J. Pinsky. 2010. Ecto-59-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation. J. Immunol. 185: 1321-1329.
50. Bar-Yehuda, S., D. Luger, A. Ochaion, S. Cohen, R. Patokaa, G. Zozulya, P. B. Silver, J. M. de Morales, R. R. Caspi, and P. Fishman. 2011. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. Int. J. Mol. Med. 28: 727-731.